Q1 2025 Vimian Group AB Earnings Call Transcript
Key Points
- Vimian Group AB (VIMGF) delivered a strong earnings growth with an 18% increase in revenue to EUR107.5 million.
- The company achieved a significant milestone by starting to trade on the large cap market on the Nasdaq main market in Stockholm.
- Specialty Pharma business showed robust performance with 10% organic growth and the launch of 23 new products.
- Veterinary Services business reported double-digit revenue growth and improved margins from 25.4% to 30.3%.
- The company improved its ESG rating from A to AA with MSCI, reflecting progress in sustainability initiatives.
- Organic growth was negatively impacted by adjustments in the annual ordering program, particularly affecting the MedTech orthopedic business in the US.
- The MedTech segment experienced an organic decline due to softness in the elective surgery market in the US.
- Cross-selling contributed less to organic growth this quarter due to order timing issues.
- The company faces potential challenges from tariffs, with roughly half of US sales impacted, though the impact on EBITDA is expected to be limited.
- There is ongoing geopolitical uncertainty and potential risks from tariffs and macroeconomic conditions that could affect future performance.
(audio in progress) Vimian Group Q1 report 2025 presentation. (Operator Instructions)
Now I will hand the conference over to the speaker's CEO, Patrik Eriksson; and CFO, Carl-Johan Zetterberg Boudrie. Please go ahead.
Good morning. It's Patrick speaking and thank you very much for joining us on our quarterly call today. We'll just jump right into it and talk a little bit about our highlights for the quarter. First and foremost, we delivered a strong earnings growth in the quarter. We're very pleased about how that developed, and we'll talk a little bit more about where it came from and how it came to be.
And as you might recall from our last time we met, we signaled that our organic revenue growth was going to be impacted by the adjustment in the annual ordering program. Therefore, our organic growth is a bit lower than you might have expected and see us do in the past. The remaining operating units that we have, the three others, all deliver double-digit organic growth in the quarter
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
